1. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
- Author
-
Roos, I, Hughes, S, McDonnell, G, Malpas, CB, Sharmin, S, Boz, C, Alroughani, R, Ozakbas, S, Buzzard, K, Skibina, O, van der Walt, A, Butzkueven, H, Lechner-Scott, J, Kuhle, J, Terzi, M, Laureys, G, Van Hijfte, L, John, N, Grammond, P, Grand'Maison, F, Soysal, A, Jensen, AV, Rasmussen, PV, Svendsen, KB, Barzinji, I, Nielsen, HH, Sejbaek, T, Prakash, S, Stilund, MLM, Weglewski, A, Issa, NM, Kant, M, Sellebjerg, F, Gray, O, Magyari, M, Kalincik, T, MSBase, SG, Danish, MSRSG, Roos, I, Hughes, S, McDonnell, G, Malpas, CB, Sharmin, S, Boz, C, Alroughani, R, Ozakbas, S, Buzzard, K, Skibina, O, van der Walt, A, Butzkueven, H, Lechner-Scott, J, Kuhle, J, Terzi, M, Laureys, G, Van Hijfte, L, John, N, Grammond, P, Grand'Maison, F, Soysal, A, Jensen, AV, Rasmussen, PV, Svendsen, KB, Barzinji, I, Nielsen, HH, Sejbaek, T, Prakash, S, Stilund, MLM, Weglewski, A, Issa, NM, Kant, M, Sellebjerg, F, Gray, O, Magyari, M, Kalincik, T, MSBase, SG, and Danish, MSRSG
- Abstract
IMPORTANCE: Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. OBJECTIVE: To evaluate whether the effectiveness of rituximab is noninferior to ocrelizumab in relapsing-remitting MS. DESIGN, SETTING, AND PARTICIPANTS: This was an observational cohort study conducted between January 2015 and March 2021. Patients were included in the treatment group for the duration of study therapy and were recruited from the MSBase registry and Danish MS Registry (DMSR). Included patients had a history of relapsing-remitting MS treated with ocrelizumab or rituximab, a minimum 6 months of follow-up, and sufficient data to calculate the propensity score. Patients with comparable baseline characteristics were 1:6 matched with propensity score on age, sex, MS duration, disability (Expanded Disability Status Scale), prior relapse rate, prior therapy, disease activity (relapses, disability accumulation, or both), magnetic resonance imaging lesion burden (missing values imputed), and country. EXPOSURE: Treatment with ocrelizumab or rituximab after 2015. MAIN OUTCOMES AND MEASURES: Noninferiority comparison of annualized rate of relapses (ARRs), with a prespecified noninferiority margin of 1.63 rate ratio. Secondary end points were relapse and 6-month confirmed disability accumulation in pairwise-censored groups. RESULTS: Of the 6027 patients with MS who were treated with ocrelizumab or rituximab, a total of 1613 (mean [SD] age; 42.0 [10.8] years; 1089 female [68%]) fulfilled the inclusion criteria and were included in the analysis (898 MSBase, 715 DMSR). A total of 710 patients treated with ocrelizumab (414 MSBase, 296 DMSR) were matched with 186 patients treated with rituximab (110 MSBase, 76 DMSR). O
- Published
- 2023